Waters Corporation Completes Strategic Merger
Waters Corporation, a prominent leader in life sciences and diagnostics, has successfully completed a merger with the Biosciences and Diagnostic Solutions businesses of Becton, Dickinson and Company. This strategic move, geared towards creating a powerhouse in the diagnostics sector, showcases Waters' commitment to innovation and excellence.
Leadership Expansion with New Board Member
As part of this transformative journey, Waters announced the appointment of Dr. Claire M. Fraser to its Board of Directors. Dr. Fraser, a renowned genome scientist with over thirty years in the field, enriches the board's expertise. Her previous role was as Director of The Institute for Genome Sciences at the University of Maryland, where she significantly advanced research in genomics.
Contributions and Expertise
Dr. Fraser has an impressive academic background, having earned a B.S. in Biology and a Ph.D. in Pharmacology. Her deep knowledge in genomics and molecular diagnostics is set to benefit Waters greatly as the company forges ahead. Chairman Flemming Ørnskov emphasized the value Dr. Fraser brings to the team, particularly in steering future growth.
Creating a Global Diagnostics Leader
The successful union of Waters and BD’s biosciences businesses has led to the formation of four distinct divisions. These divisions—Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences—focus on high-volume testing and adhere to strict regulatory standards.
Overview of the New Divisions
Each division integrates advanced scientific teams and resources dedicated to various applications. For instance, Waters Analytical Sciences emphasizes physical molecular characterization, while Waters Biosciences is poised to advance cellular analysis techniques. This restructuring positions Waters strongly to meet the increasing demands in therapeutics, diagnostics, and environmental safety.
Transaction Highlights
The merger was executed via a Reverse Morris Trust transaction. As a result of this deal, Waters shareholders hold 60.8% of the combined entity, marking a significant milestone for the company. Meanwhile, BD shareholders will see their stake adjusted as they receive shares of Waters common stock based on their previous holdings.
Financial Advisory and Legal Support
Barclays served as the financial advisor throughout this merger process while Kirkland & Ellis LLP provided essential legal counsel, ensuring a smooth transition and integration of the companies.
About Waters Corporation
Waters Corporation is dedicated to pushing the boundaries of scientific discovery by providing innovative analytical technologies and services. With an emphasis on improving health and safety through scientific advancements, the company focuses on regulated, high-volume testing. Waters collaborates with organizations worldwide, ensuring reliable diagnostics and effective solutions for better healthcare outcomes.
Commitment to Innovation
With around 16,000 colleagues worldwide, Waters embodies a culture of relentless innovation and commitment. Every member of the team plays a pivotal role in transforming scientific challenges into breakthroughs that enhance the quality of life for communities globally.
Frequently Asked Questions
What is the main focus of the Waters and BD merger?
The merger aims to form a global leader in life sciences and diagnostics, particularly in high-volume testing for regulated applications.
Who is Dr. Claire M. Fraser?
Dr. Fraser is a renowned genome scientist appointed to the Waters Board of Directors, bringing extensive knowledge in genomics and diagnostics.
How many divisions has Waters established post-merger?
Waters has created four divisions to streamline its offerings and enhance its capabilities in various scientific fields.
How does the merger impact Waters shareholders?
Waters shareholders will own 60.8% of the combined company after the successful merger.
What is Waters Corporation known for?
Waters Corporation is recognized for its innovative analytical technologies and commitment to improving global health through scientific advancements.
